Arrestin Pathways as Drug Targets - Progress in Molecular Biology and Translational Science - page 478

39. Azzi M, Charest PG, Angers S, et al. Beta-arrestin-mediated activation of MAPK by
inverse agonists reveals distinct active conformations for G protein-coupled receptors.
Proc Natl Acad Sci USA . 2003;100:11406- 11411.
40. Kendall RT, Strungs EG, Rachidi SM, et al. The b -arrestin pathway-selective angio-
tensin AT 1A receptor agonist, Sar 1 Ile 4 Ile 8 -AngII, regulates a robust G protein-
independent signaling network. J Biol Chem . 2011;286:19880 - 19891.
41. Christensen GL, Kelstrup CD, Lyngsø C, et al. Quantitative phosphoproteomics dis-
section of seven-transmembrane receptor signaling using full and biased agonists. Mol
Cell Proteomics . 2010;9:1540 - 1553.
42. Rajagopal K, Whalen EJ, Violin JD, et al. Beta-arrestin2-mediated inotropic effects of
the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA .
2006;103:16284 - 16289.
43. Aplin M, Christensen GL, Schneider M, et al. Differential extracellular signal-regulated
kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct pheno-
types of cardiac myocytes. Basic Clin Pharmacol Toxicol . 2007;100:296 - 301.
44. Gesty-Palmer D, Yuan L, Martin B, et al. b -arrestin-selective G protein-coupled
receptor agonists engender unique biological efficacy in vivo. Mol Endocrinol .
2013;27:296 - 314.
45. Tam CS, Heersche JN, Murray TM, Parsons JA. Parathyroid hormone stimulates the
bone apposition rate independently of its resorptive action: differential effects of inter-
mittent and continuous administration. Endocrinology . 1982;110:506 - 512.
46. Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition
of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner
Res . 1992;7:65 - 72.
47. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hor-
mone increases bone formation in adult rats by activation of bone lining cells. Endocri-
nology . 1995;136:3632- 3638.
48. Deng ZL, Sharff KA, Tang N, et al. Regulation of osteogenic differentiation during
skeletal development. Front Biosci . 2008;13:2001 - 2021.
49. Lian JB, Stein GS, Javed A, et al. Networks and hubs for the transcriptional control of
osteoblastogenesis. Rev Endocr Metab Disord . 2006;7:1 - 16.
50. Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for
bone metabolism. Trends Endocrinol Metab . 2004;15:60 - 65.
51. Ferrari SL, Pierroz DD, Glatt V, et al. Bone response to intermittent parathyroid
hormone is altered in mice null for beta-arrestin2. Endocrinology . 2005;146:

1854- 1862.
52. Mohan S, Kutilek S, Zhang C, et al. Comparison of bone formation responses to para-
thyroid hormone(1 - 34), (1- 31), and (2 - 34) in mice. Bone . 2000;27:471- 478.
53. Sebastian EM, Suva LJ, Friedman PA. Differential effects of intermittent PTH(1 - 34)
and PTH(7 - 34) on bone microarchitecture and aortic calcification in experimental
renal failure. Bone . 2008;43:1022 - 1030.
54. Violin JD, DeWire SM, Yamashita D, et al. Selectively engaging b -arrestins at the
angiotensin II type 1 receptor reduces blood pressure and increases cardiac perfor-
mance. J Pharmacol Exp Ther . 2010;335:572 - 579.
55. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, Koch WJ. An adrenal beta-
arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone
production in vitro and in vivo. Proc Natl Acad Sci USA . 2009;106:5825 - 5830.
56. Appleton KM, Luttrell LM. Emergent biological properties of arrestin pathway-
selective biased agonism. J Rec Signal Trans . 2013.
57. Bassingthwaite JB, Liebovitch LS, West BJ. Fractal Physiology. New York: Oxford
University Press Inc.; 1994.